We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

News · April 15, 2021

Three-Drug Regimen Treats Cystic Fibrosis in Younger Children

Elexacaftor/tezacaftor/ivacaftor well tolerated in children aged 6 through 11 years with cystic fibrosis and at least one F508del-CFTR allele



Further Reading